10:08:35 Europe / Stockholm
2023-05-26 09:15:00

Copenhagen-based biotechnology company Curasight recently released its Q1 2023 report, unveiling a significant stride in its continued journey towards improving cancer diagnosis and treatment. The quarter's highlight was undoubtedly the company's partnership agreement with Curium. This move not only reinforced the technological strength of its uTRACE platform but also strategically positioned Curasight to better serve patients on a global scale.

Read the full article at biostock.se:


This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se